News from SOLVO

July 23, 2019

The first half of 2019 has been an exciting period for SOLVO. Becoming part of the Charles River family means new opportunities for spreading our expertise about membrane transporters to new clients and also for supporting our existing customers “Every Step Of The Way” through a vastly expanded catalog of nonclinical services. The feedback from our clients so far has been overwhelmingly positive, and we look forward to future expansion and enhancement of our ADME-Tox portfolio as a result.


During the rest of the year we are keenly looking forward to meeting you in person at various events around the globe:
The SOLVO team invites you to meet them at the International ISSX meeting in Portland, OR (28 Jul-1 Aug). Our scientists exchange knowledge with other thought leaders on the field at the ITTS – BioParadigms in Luzern (04-09 Aug). Fall season starts with a massive delegation attending the EUROTOX event in Helsinki (08-11 Sep) followed by the annual DMDG open meeting in Cambridge (17-20 Sep). At the same time SOLVO will be represented at the Society for the Study of Xenobiotics, India conference in Bangalore (18-21 Sep) and at the Land O’ Lakes Drug Metabolism and Applied PK Conference in Madison, WI (17-20 Sep). The next chance to catch up with us will be in Lyon at the GMP annual symposium (16-18 Oct), while you can also greet us in Jeju Island, Korea at the KSNS Workshop (24-25 Oct). Please look for our booth at the AAPS Annual Meeting (PharmSci 360) in San Antonio, TX (3-6 Nov), too. The final event of the year is the JSSX meeting in Tsukuba (09-12 Dec).


We are excited to produce our 9th and 10th programs this year in the Meet the Experts Transporter Conference series.  These events bring thought leaders in the field of transporters from industry and academia to present on cutting-edge transporter science and translational applications.  We invite you to join us at one of these highly-focused programs: Cambridge, MA (Sept 3-5), and Seoul, Korea (Nov 14).  For additional information and registration, click here.


Date: July 25, 2019, 7am PDT/10am
EDT/3pm BST/4pm CEST

Title: Using DILIsym to Predict Hepatotoxicity
Risk During Pre-clinical Development

Presenter: Dr. Paul Michalski, GSK

You are invited to join us for the next installment in our educational webinar series.  Dr. Paul Michalski, Investigator/Quantitative Systems Pharmacology Engineer from GlaxoSmithKline, will discuss a proof-of-concept study carried out to determine the utility of DILIsym as a screening tool in early pre-clinical development. He will provide an overview of the DILIsym program and highlight where DILIsym can provide value as a pre-candidate screening tool, as well as its inherent limitations.  Registration is free, but seats are limited--reserve your spot soon! Click here to register

As a reminder, over 20 previous webinar recordings are available covering a variety of transporter protein and related topics, such as: novel in vitro models, drug metabolism, predictive in vitro toxicity, DDI, absorption & disposition, natural products interactions, and others.
Two of our most recent presentations:
Highlights of ITC3: Clinically-Relevant Transporters, Clinical Probes and DDI Evaluation
Presenter: Maciej J. Zamek-Gliszczynski, Ph.D.
Role of Organic Anionic Transporter (OAT2) in the Hepatic Clearance of Anionic/Zwitterionic Drugs – ‘A missing piece of the puzzle’
Presenter: Manthena V. Varma, M.S., Ph.D.
Click here to view a full list of recorded webinars at our online Knowledge Center


Plans for expanding on bioanalytical capacity and introduction of platform technologies at SOLVO were successfully implemented during the first half of 2019. Early in the year a new SCIEX 5500 QTRAP Triple quad linear ion trap Mass Spectrometer was installed and put into service. 
More recently, we have coupled this to a brand new Phytronix Luxon Ion Source S-960. We’re quite excited about this expansion, not only because of its futuristic look, but also because the average time per sample is less than 10 seconds compared to an average of 3 minutes in a regular LC-MS/MS analysis, significantly increasing our throughput and allowing us to serve our clients even better! It’s worth noting that this is one of only six S-960 units currently installed in Europe, which underscores SOLVO’s ambition to be among the most well-equipped CROs in the field.
Further building on this philosophy and recognizing the importance of increased capacity and turnaround times, we have installed a state-of-the-art Hamilton Microlab® STAR™ liquid handling platform. The first transporter assays have already been programmed on this, allowing fully automated transporter assays to be conducted under highly standardized conditions and at high throughput, and we look forward to launching the first assays on this new platform in the near future!


Next entry: Meet SOLVO at the 12th International ISSX Meeting in Portland!

Previous entry: Webinar announcement: Using DILIsym to Predict Hepatotoxicity Risk During Pre-clinical Development

More News

Read all news in the archive